Therapeutic strategy for treating glioblastoma by targeting the LINC complex
This technology identifies the LINC complex as a therapeutic target for glioblastoma to suppress tumor progression and prevent the emergence of a therapy-resistant mesenchymal state.
Unmet Need: Novel therapies strategy for glioblastoma
Glioblastoma is the most common and aggressive brain tumor, with a poor prognosis and inevitable recurrence. Although surgery, radiation, and chemotherapy remain the standard of care, diffuse tumor infiltration limits complete surgical removal, and a subset of glioblastoma cells can enter a treatment-resistant, stem-cell-like state that acts as a reserve pool for cancer proliferation following treatment. As a result, there is a critical need for novel therapeutic strategies that specifically target the mechanisms underlying glioblastoma progression and therapy resistance.
The Technology: Specific gene therapy to eliminate glioblastoma cells
This technology identifies the LINC complex as a novel therapeutic target for glioblastoma. Nesprin-2, a component of the LINC complex that connects the nucleus to the cytoskeleton, is critical for glioblastoma cell migration and proliferation. Unlike most normal brain cells, which predominantly express nesprin-1, glioblastoma cells rely on nesprin-2, creating a tumor-specific therapeutic vulnerability. RNA interference targeting nesprin-2 reduces tumor growth size and proliferation while suppressing the therapy-resistant, stem-cell-like state that drives disease recurrence.
This technology has been validated with human glioblastoma patient samples in vitro and with mouse models in vivo.
Applications:
- Antisense oligonucleotide therapies for glioblastoma
- AAV-mediated miRNA gene therapies
- Targeted CRISPR-based therapeutic strategies
- Research tool for studying glioblastoma cell proliferation, migration and therapy resistance
Advantages:
- Prevents the emergence of therapy-resistant mesenchymal-like cell state
- Targets a novel therapeutic pathway for glioblastoma treatment
- High tumor specificity through selective targeting of nesprin-2
Lead Inventor:
Patent Information:
Patent Pending
Related Publications:
Tech Ventures Reference:
IR CU26167
Licensing Contact: Jerry Kokoshka